Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies
Partners ONK Therapeutics To Develop Five Candidates
Executive Summary
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.